Sanofi-Aventis to cut 1,400 sales reps

Share this article:

Sanofi-Aventis will winnow its US sales forces down by 1,400, the company announced on Friday. The move follows layoffs in April of around 400 reps, and brings the total sales force headcount down to roughly 4,000. The Paris-based company employed approximately 6,500 US-based reps just one year ago.

The restructuring will reduce Sanofi's US pharmaceutical operations by 1,700 positions in total – 1,400 reps and 300 home office employees, according to Jack Cox, a Sanofi spokesperson – and includes a shift in resources from “late life-cycle, value-driver products” to growth areas like oncology and diabetes, said Cox, adding that Actonel, Aplenzin, Avapro, Avalide and Plavix are among the products slated to lose promotional resources. “We believe making these changes now will make us the right size for our product portfolio and give us a strong organizational structure to meet the challenges we anticipate during the next couple of years,” said Cox in an email.

In addition to oncology and diabetes, Sanofi will also focus on atrial fibrillation – specifically, Multaq – and OTC consumer healthcare products sold by Chattem, a US-based subsidiary, according to Cox. In March, Sanofi completed its $1.9 billion acquisition of Tennessee-based Chattem, makers of Gold Bond, Icy Hot, Dexatrim and Unisom, among other products, and hopes to use Chattem's marketing and distribution channels as a conduit for future OTC conversions, beginning with Allegra, according to a company statement in March.

Sanofi is currently attempting a hostile takeover of Genzyme Corp., and bid $18.5 billion for the Massachusetts-based biotech in late August. Genzyme has urged shareholders to reject that offer.

In other news, Sanofi Pasteur, the vaccines division of the Sanofi-Aventis Group, was awarded a three-year, $56.94 million contract by the US Department of Health And Human Services on Friday, for maintaining the resources needed to manufacture pandemic flu vaccines at full capacity, in the event that a vaccine is needed, according to a release.

Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...